Alnylam Pharma (DUL) Revenue
Alnylam Pharma Revenue
Alnylam Pharma had a revenue of 1.46B in the quarter ending Sep 30, 2026, with 12.95%. This bring the company's revenue in the last twelve months to 5.01B, Increased 4.35%. In the fiscal year ending Dec 31, 2025, Alnylam Pharma had annual revenue of 3.71B with 65.19% growth.
- Revenue (ttm)
- 5.01B
- Revenue Growth
- 50.34%
- P/S Ratio
- 5.31
- Revenue/Employee
- EUR 1,485,575
- Employees
- 2,500
- Market Cap
- EUR 19.72B
Revenue Chart
Alnylam Pharma Revenue - Annual
Revenue History
| Fiscal End Date | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.71B | 1.47B | 65.19% |
| Dec 31, 2024 | 2.25B | 419.95M | 22.97% |
| Dec 31, 2023 | 1.83B | 790.87M | 76.23% |
| Dec 31, 2022 | 1.04B | 193.13M | 22.88% |
| Dec 31, 2021 | 844.29M | 351.43M | 71.31% |
| Dec 31, 2020 | 492.85M | 273.10M | 124.28% |
| Dec 31, 2019 | 219.75M | 144.84M | 193.36% |
| Dec 31, 2018 | 74.91M | -15.00M | -16.69% |
| Dec 31, 2017 | 89.91M | ― | ― |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.